FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Immutep Limited Rise on Positive Breast Cancer Data”
Immutep Limited (NASDAQ: IMMP) opened 224% higher than its previous close after announcing that its Chinese partner, EOC Pharma is to commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.
The trial will evaluate Immutep’s lead product candidate eftilagimod alpha in combination with paclitaxel in HER2-negative/HR positive metastatic breast cancer patients.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients.
For more information, please visit: Immutep Limited
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.